Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDA NASDAQ:BFRI NASDAQ:ELAB NASDAQ:IMCC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$1.68-1.8%$2.18$1.63▼$4.66$9.41M0.81645,528 shs86,257 shsBFRIBiofrontera$0.95-6.9%$0.78$0.54▼$2.22$10.34M0.5113,022 shs88,362 shsELABPMGC$1.89-1.3%$2.20$1.81▼$546.00$2.63M0.17145,716 shs11,402 shsIMCCIM Cannabis$2.56+2.0%$2.91$1.29▼$7.12$10.15M2.260,009 shs43,468 shs10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia-1.75%-21.50%-26.64%-41.05%-40.21%BFRIBiofrontera-6.86%-12.04%+30.32%+36.71%-18.80%ELABPMGC-1.31%-9.81%-18.04%-20.46%-99.62%IMCCIM Cannabis+1.99%-2.29%-24.04%+55.15%-16.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia2.8863 of 5 stars3.83.00.00.01.52.50.6BFRIBiofrontera1.6723 of 5 stars3.53.00.00.00.60.00.6ELABPMGC0.2403 of 5 stars0.02.00.00.01.70.00.6IMCCIM Cannabis0.2508 of 5 stars0.05.00.00.00.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.001,388.10% UpsideBFRIBiofrontera 3.00Buy$2.75189.47% UpsideELABPMGC 0.00N/AN/AN/AIMCCIM Cannabis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ELAB, BCDA, BFRI, and IMCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BFRIBiofronteraBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $2.75(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$60K154.00N/AN/A$0.18 per share9.33BFRIBiofrontera$38.00M0.25N/AN/A$0.57 per share1.67ELABPMGC$1.71M1.52N/AN/A$11.53 per share0.16IMCCIM Cannabis$54.47M0.19N/AN/A$1.03 per share2.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)BFRIBiofrontera-$17.76M-$2.26N/AN/AN/A-30.33%-305.13%-82.67%8/13/2025 (Estimated)ELABPMGC-$6.25M-$433.87N/A∞N/AN/A-77.80%-59.17%8/13/2025 (Estimated)IMCCIM Cannabis-$7.72M-$0.64N/AN/AN/A-9.10%-122.96%-11.69%8/12/2025 (Estimated)Latest ELAB, BCDA, BFRI, and IMCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025BFRIBiofrontera-$0.45N/AN/AN/A$8.30 millionN/A5/15/2025Q1 2025BFRIBiofrontera-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million5/15/2025Q1 2025IMCCIM Cannabis-$0.2540$0.06+$0.3140$0.06$11.45 million$8.69 million5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/14/2025Q1 2025ELABPMGCN/A-$2.90N/A-$2.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/AELABPMGCN/AN/AN/AN/AN/AIMCCIM CannabisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.360.36BFRIBiofrontera8.991.400.80ELABPMGCN/A8.978.97IMCCIM Cannabis0.100.720.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%BFRIBiofrontera10.08%ELABPMGC22.22%IMCCIM Cannabis7.68%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%BFRIBiofrontera1.20%ELABPMGC0.60%IMCCIM Cannabis5.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.50 million4.40 millionOptionableBFRIBiofrontera7010.14 million10.02 millionNo DataELABPMGC181.38 million1.37 millionN/AIMCCIM Cannabis3404.05 million3.81 millionNot OptionableELAB, BCDA, BFRI, and IMCC HeadlinesRecent News About These CompaniesIM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ETAugust 4, 2025 | prnewswire.comIM Cannabis Closes Private Placement for Gross Proceeds of Approximately US$4.1 MillionJuly 31, 2025 | prnewswire.comIM CANNABIS ANNOUNCES FILING OF SHELF REGISTRATION STATEMENT ON FORM F-3July 11, 2025 | prnewswire.comIM Cannabis Announces the Signing of a Loan Agreement and Appointment of Oz Adler to Board of DirectorsJuly 9, 2025 | prnewswire.comIM Cannabis Provides Corporate UpdatesJuly 1, 2025 | prnewswire.comIM Cannabis (NASDAQ:IMCC) Stock, Earnings Estimates, EPS, And RevenueJune 1, 2025 | benzinga.comIM Cannabis Stock Price, Quotes and Forecasts | NASDAQ:IMCC | BenzingaJune 1, 2025 | benzinga.comCSE Bulletin: Delist - IM Cannabis Corp. (IMCC)May 28, 2025 | newsfilecorp.comNIM Cannabis Corp.: IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities ExchangeMay 28, 2025 | finanznachrichten.deIM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities ExchangeMay 28, 2025 | prnewswire.comIM Cannabis Provides Corporate UpdatesMay 27, 2025 | prnewswire.comIM Cannabis Corp. (IMCC) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comIM Cannabis Reports First Quarter Financial ResultsMay 15, 2025 | prnewswire.comIM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus TransactionMay 7, 2025 | prnewswire.comIM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ETMay 6, 2025 | prnewswire.comIM Cannabis Provides Corporate UpdatesApril 11, 2025 | prnewswire.comIM Cannabis 2024 net loss ticks up despite successful cost-cutting initiativesMarch 31, 2025 | greenmarketreport.comGIM Cannabis Corp. (IMCC) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comIM Cannabis Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 31, 2025 | prnewswire.comIM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ETMarch 20, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELAB, BCDA, BFRI, and IMCC Company DescriptionsBioCardia NASDAQ:BCDA$1.68 -0.03 (-1.75%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.71 +0.03 (+1.79%) As of 08:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Biofrontera NASDAQ:BFRI$0.95 -0.07 (-6.86%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.95 0.00 (0.00%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.PMGC NASDAQ:ELAB$1.88 -0.03 (-1.31%) Closing price 08/7/2025 03:50 PM EasternExtended Trading$1.90 +0.01 (+0.80%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.IM Cannabis NASDAQ:IMCC$2.56 +0.05 (+1.99%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$2.52 -0.04 (-1.37%) As of 08:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
